Research programme: bacterial translocase inhibitors - Sankyo/Sequella
Alternative Names: SQ641; SQ922Latest Information Update: 28 Mar 2022
At a glance
- Originator Daiichi Sankyo Company
- Developer Sequella
- Class Aminoglycosides; Anti-inflammatories; Antibacterials; Nucleosides
- Mechanism of Action Phospho-N-acetylmuramoyl pentapeptide transferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Clostridium difficile infections; Crohn's disease
- Discontinued Nontuberculous mycobacterium infections
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Clostridium-difficile-infections in USA
- 28 Feb 2020 No recent reports of development identified for preclinical development in Crohn's-disease in USA
- 05 Feb 2018 SQ 641 is still in preclinical development for Crohn's disease in USA